Surging Green Early, Low Float (MIRA) Could Enter Breakout Mode (Breaking News Today)

MIRA is off to a strong start today and needs immediate attention for 3 key reasons. Surging Green Early, Low Float (MIRA) Could Enter Breakout Mode (Breaking News Today) $22.70 Zacks SCR Analyst Target - [Full Report]( December 4th Dear Reader, MIRA is off to a strong start today and needs immediate attention for 3 key reasons. First, its [low float](. With a float under 9Mn shares, volatility will need to be on watch at all times. Second, its analyst [$22.70 target](. That target represents a potential upside over 450% from MIRA's closing valuation this past Friday. Third, the company's [huge news]( from this morning. As this news continues to circulate, it could draw a ton of attention to a profile flying below Wall Street's radar right now. There's a ton of potential catalysts that could spark MIRA near term. For now, read my initial MIRA report below and get it front and center quickly today. -----  Let's go... Trading on the Nasdaq Capital Market, we've uncovered a potential wrecking ball. With a low float of fewer than 9Mn shares, volatility could end up being an explosive catalyst to watch for closely. Speaking of potential volatility, it was quite recently that this profile rocketed short term. We're talking around 250+% in under a week... Could another big move be right around the corner? [One analyst]( seems to think it's possible. Recently updating and upgrading his target to $22.70, this Nasdaq breakout idea may just hold a crazy amount of upside potential from its closing valuation Friday. Like 450+% potential upside... But this might be the most important bit of info to focus on right now. This company is on the disruptor forefront and could soon be ready to take on these TAM battles: With these two TAM's up for grabs, this little-known company might not fly under the radar for much longer as [human trials]( will be ramping up in 2024 for their next generation T-H-C analog. Drop everything right now and pull up: MIRA Pharmaceuticals, Inc. (MIRA) MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company developing an unscheduled novel synthetic T-H-C analog. This novel compound is currently under investigation for potentially treating adults suffering from anxiety and cognitive decline, often associated with early-stage dementia. Developing The Next Generation FDA Approved Novel Synthetic T-H-C Analog MIRA Pharmaceuticals, Inc. is a life sciences company focused on the development of MIRA1a, a novel synthetic T-H-C analog. MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and neuropathic pain without impurities or the negative side effects associated with cann-a-bis ("CB") plant extracts. MIRA1a is classified as an unscheduled drug by the U.S. Drug Enforcement Administration (DEA). Market Opp. - Summary of U.S. Epidemiology The eligible patient pool analysis for MIRA1a highlights a potential large patient pool looking for potential treatments to their conditions: U.S. Le.gal MJ Market Initial dual path focus: Potentially winning in traditional markets and the T-H-C analog markets using a safe, effective and FDA-approved treatment option. Therapeutic Focus Areas MIRA1a is under evaluation for three key therapeutic areas with high disease burden and significant unmet needs: Neuropathic Pain Neuropathic Pain is a complex pain condition that arises from dysfunction or damage to the nervous system. It is a pain state that can continue even when the initial cause of the pain, such as an injury or disease, has healed or been treated. It represents a malfunction in the nerve's signaling rather than a response to continued harm. Affecting approximately 7-10% of the general population. Examples include diabetic peripheral neuropathy, postherpetic neuralgia, and multiple sclerosis related neuropathy. Existing treatments may involve medications like anticonvulsants, which can reduce the excitability of nerves, thereby dampening abnormal electrical activity, or antidepressants, which increase serotonin and norepinephrine levels that modulate the way the brain perceives pain. However, their effectiveness can be limited, and they might carry side effects. Opiates are used less frequently due to addiction risks. Developing targeted and efficient therapies for neuropathic pain stands as a priority for numerous pharmaceutical companies to address this common source of suffering and morbidity for treatment-resistant cases. Innovative strategies, including cann-a-binoid therapies, are under exploration to tackle the distinctive challenges posed by this type of pain. Anxiety and Cognitive Decline in the Elderly Anxiety disorders are chronic conditions marked by an excessive & persistent sense of apprehension, with physical symptoms such as sweating, palpitations, and feelings of stress. ~40 million U.S. adults have an anxiety disorder, including phobias, Social Anxiety Disorder, PTSD, Generalized Anxiety Disorder, and Panic Disorder. Standard treatment leverages cognitive-behavioral therapy, though pharmacological options include. SSRIs, SNRIs, and TCAs. Cognitive Impairment Cognitive Impairment encompasses conditions marked by notable decline in one's cognitive abilities including Alzheimer's disease and dementia. ~16 million people in the US are living with cognitive impairment. Current treatments for cognitive impairment do not temporarily restore lost function and are only capable of delaying the progression of the disease. Anticipated Timeline Pre-clinical work is underway and expected to be completed by Q1’24. Positioning MIRA for an initial IND filing in Q3 2024. Grab Key Sources Here: [Company Website.]( [Company Presentation.]( ----- The Top 3 Potential Catalysts To Focus On Right Now! #1. MIRA is a low float profile (volatility will need to be on watch.) As of Friday's closing bell, [Yahoo Finance]( was reporting MIRA to have a float of 8.84Mn shares. Why is this important? One word: Volatility. When a profile has a float this small, volatility can create an environment for explosive intraday and short term chart moves. One thing that can influence such a move is company news (whether good or bad). In fact, it could be why MIRA was able to move over $4.00+ short term recently... ----- #2. Zacks SCR analyst target of $22.70 starts making headlines. Last week, Zacks Small-Cap Research analyst, Brad Sorensen, updated a [research report]( on MIRA. In it, he highlights why MIRA has a $22.70 price target which suggests over 450% potential upside from its closing valuation Friday. Here's a key highlight: - Adding to its continuing pursuit of the company’s primary treatment, MIRA1, MIRA announced that it has acquired an exclusive license to develop and commercialize a product commonly known as Ketamir, which, in layman’s terms, is a potential derivative of the antidepressant ket-a-mine that has shown indications of having fewer side effects, working more rapidly, and having the opp. to impact millions of patients that have not responded to other, existing treatments. The terms of the deal appear to us to be fashioned in a way that is low risk for MIRA with the potential for a very high return. ----- #3. Last week's major news announcement could provide an incredible breakout spark near term. Check it out: New Data from IQVIA Supports Potential $3Bn Annual Market "This positive financial outlook bolsters our confidence in advancing Ketamir-2's clinical development," said Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals. "We are poised to make a significant impact to a market that urgently needs innovative solutions." Annupama Kumar, MBBS, Vice President of Drug Development at MIRA Pharmaceuticals, added: "Oral delivery of Ketamir-2 could transform depression management, offering more consistent and accessible treatment for patients. This advancement is not just a milestone for MIRA Pharmaceuticals, but a beacon of hope for millions battling severe depression." [Read the full article here.]( ----- Coverage is officially initiated on MIRA Pharmaceuticals, Inc. (MIRA). When updates pop up this week, I'll get them out to you quickly. Talk soon, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 12/3/23 and ending on 12/4/23 to publicly disseminate information about (MIRA) via Website, Email and SMS. SWN Media LLC was paid twenty thousand USD via bank wire transfer. We own zero shares of (MIRA). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Outside the Box Capital, TD Media LLC has been hired for a period beginning on 12/03/2023 and ending on 12/04/2023 to publicly disseminate information about (MIRA:US) via digital communications. We have been paid fifty thousand dollars USD. We own zero shares of (MIRA:US). [( Fierce | 4834 NW 2nd Ave, Unit #388, Boca Raton, FL 33431 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net